Vioquest Pharmaceuticals Inc (VOQP) 재무

VioQuest Pharmaceuticals, Inc. engages in the acquisition, development and commercialization of clinical stage drug therapies for the molecular basis of cancer and side effects of cancer treatment. The company is headquartered in Basking Ridge, New Jersey and currently employs 3 full-time employees. The Company’s lead compound under development is Xyfid (1% topical uracil) for the treatment and prevention of Hand-Foot Syndrome (HFS). In parallel, Xyfid is also being developed to treat dry skin conditions and manage the burning and itching associated with various diseases of the skin or dermatoses. In addition, VioQuest Pharmaceuticals is developing VQD-002 (triciribine phosphate monohydrate or TCN-P), a small molecule anticancer compound that inhibits activation of protein kinase B (PKB or AKT), a key component of a signaling pathway known to promote cancer cell growth and survival, as well as resistance to chemotherapy and radiotherapy. On July 16, 2007, the Company completed the sale of Chiral Quest, Inc. to Chiral Quest Acquisition Corp.